BR0317659A - Derivados de pirazol como inibidores de fator xa - Google Patents

Derivados de pirazol como inibidores de fator xa

Info

Publication number
BR0317659A
BR0317659A BR0317659-2A BR0317659A BR0317659A BR 0317659 A BR0317659 A BR 0317659A BR 0317659 A BR0317659 A BR 0317659A BR 0317659 A BR0317659 A BR 0317659A
Authority
BR
Brazil
Prior art keywords
factor
compounds
formula
inhibitors
vila
Prior art date
Application number
BR0317659-2A
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
David William Will
Hans Matter
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02028915A external-priority patent/EP1433788A1/en
Priority claimed from EP03011308A external-priority patent/EP1479678A1/en
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0317659A publication Critical patent/BR0317659A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

"DERIVADOS DE PIRAZOL COMO INIBIDORES DE FATOR XA". A presente invenção refere-se a compostos da fórmula I, em que R¬ 0¬; R¬ 1¬; R¬ 2¬; R¬ 3¬; R¬ 4¬; Q; V, G e M tem os significados indicados nas reivindicações. Os compostos da fórmula I são compostos farmacologicamente ativos valiosos. Eles demonstram um forte efeito antibrombótico e são apropriados, por exemplo, para a terapia e profilaxia de distúrbios cardiovasculares como doenças tromboembolíticas ou restenoses. Eles são inibidores reversíveis das enzimas de coagulação do sangue fator Xa (FXa) e/ou fator VIIa (FVIIa), e podem geralmente ser aplicados em condições em que uma atividade indesejada de fator Xa e/ou fator Vila está presente ou para a cura ou prevenção da qual uma inibição de fator Xa e/ou fator Vila é pretendida. A invenção além disso refere-se a processos para a preparação de compostos da fórmula I, seu uso, particularmente como ingredientes ativos em fármacos, e preparações farmacêuticas compreendendo os mesmos.
BR0317659-2A 2002-12-23 2003-12-10 Derivados de pirazol como inibidores de fator xa BR0317659A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02028915A EP1433788A1 (en) 2002-12-23 2002-12-23 Pyrazole-derivatives as factor Xa inhibitors
EP03011308A EP1479678A1 (en) 2003-05-19 2003-05-19 Pyrazole-derivatives as factor xa inhibitors
PCT/EP2003/013979 WO2004056815A1 (en) 2002-12-23 2003-12-10 PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BR0317659A true BR0317659A (pt) 2005-12-06

Family

ID=32683809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317659-2A BR0317659A (pt) 2002-12-23 2003-12-10 Derivados de pirazol como inibidores de fator xa

Country Status (13)

Country Link
EP (1) EP1581523B1 (pt)
JP (1) JP4585448B2 (pt)
AR (1) AR042648A1 (pt)
AT (1) ATE444292T1 (pt)
AU (1) AU2003292218A1 (pt)
BR (1) BR0317659A (pt)
CA (1) CA2511321A1 (pt)
DE (1) DE60329529D1 (pt)
IL (1) IL169323A0 (pt)
MX (1) MXPA05006200A (pt)
PE (1) PE20040925A1 (pt)
TW (1) TW200505914A (pt)
WO (1) WO2004056815A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
DE102004047255A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Prolinderivate
US7446210B2 (en) 2004-10-26 2008-11-04 Janssen Pharmaceutica N.V. Factor Xa compounds
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1814860B1 (en) * 2004-10-29 2009-06-03 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
EP2395000A1 (en) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
EP1724269A1 (en) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
CA2613522A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
WO2009080226A2 (en) * 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
JP5560202B2 (ja) * 2007-12-26 2014-07-23 サノフイ Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
JP5432890B2 (ja) 2008-04-04 2014-03-05 武田薬品工業株式会社 複素環誘導体及びその用途
ES2552549T3 (es) * 2008-04-23 2015-11-30 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida para el tratamiento de trastornos metabólicos
UY33200A (es) 2010-01-26 2011-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
CN104940200B (zh) 2010-03-30 2019-06-28 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
UY33874A (es) 2011-01-26 2012-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
PT2736888E (pt) 2011-07-26 2016-02-17 Sanofi Sa Derivados do ácido 3-heteroaroilamino-propiónico e o seu uso como produtos farmacêuticos
WO2013014205A1 (en) 2011-07-26 2013-01-31 Sanofi Substituted 3 - (thiazole - 4 - carbonyl) - or 3 - (thiazole - 2 - carbonyl) aminopropionic acid derivatives and their use as pharmaceuticals
WO2013072327A1 (en) 2011-11-14 2013-05-23 Sanofi Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
CN110423221A (zh) 2013-03-15 2019-11-08 维颂公司 作为凝血酶抑制剂的卤代吡唑
MX2015012867A (es) 2013-03-15 2016-06-10 Verseon Corp Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
WO2014154727A1 (en) 2013-03-28 2014-10-02 Sanofi Biaryl-propionic acid derivatives and their use as pharmaceuticals
CA2907903A1 (en) 2013-03-28 2014-10-02 Sanofi Biaryl-propionic acid derivatives and their use as pharmaceuticals
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1045846B1 (en) * 1997-11-28 2003-05-02 Lg Chemical Limited Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
JP2001526268A (ja) * 1997-12-22 2001-12-18 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての、オルト−置換Ｐ１を有する、窒素含有複素環式芳香族化合物
PT1140941E (pt) * 1998-12-23 2005-02-28 Bristol Myers Squibb Pharma Co Heterociclicos que contem azoto como inibidores do factor xa
CN1454211A (zh) * 1999-07-16 2003-11-05 布里斯托尔-迈尔斯斯奎布药品公司 作为Xa因子抑制剂的含氮杂双环化合物
MX228790B (es) * 1999-09-17 2005-06-30 Millennium Pharm Inc Inhibidores del factor xa.
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
US6599926B2 (en) * 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
WO2002085356A1 (en) * 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-[3, 4-c]-pyrid in-7-ones as factor xa inhibitors

Also Published As

Publication number Publication date
AU2003292218A1 (en) 2004-07-14
ATE444292T1 (de) 2009-10-15
WO2004056815A1 (en) 2004-07-08
JP4585448B2 (ja) 2010-11-24
TW200505914A (en) 2005-02-16
EP1581523B1 (en) 2009-09-30
PE20040925A1 (es) 2004-12-24
EP1581523A1 (en) 2005-10-05
AR042648A1 (es) 2005-06-29
MXPA05006200A (es) 2005-08-19
DE60329529D1 (de) 2009-11-12
JP2006511608A (ja) 2006-04-06
CA2511321A1 (en) 2004-07-08
IL169323A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
BR0317659A (pt) Derivados de pirazol como inibidores de fator xa
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
CL2004001080A1 (es) COMPUESTOS DERIVADOS DE INDAZOL, INHIBIDORES DEL FACTOR Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA Y OTRAS.
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
BR0111264A (pt) Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.